Clinical trial NCT06950281: Low Sodium Oxybate as a Treatment for Nocturnal Cluster Headache
Official title: Low Sodium Oxybate Use for Nocturnal Cluster Headache: Safety, Efficacy and Tolerability of JZP-258 (XYWAV) - a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Bi-center Study.
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Chronic Cluster Headache
Lead sponsor: Leiden University Medical Center
Sponsor class: OTHER
First posted: 2025-04-30
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: An 18 week, randomized, double-blind, placebo- controlled study.
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to evaluate the efficacy of low sodium oxybate (LXB) (brand name Xywav) in the treatment of (nocturnal) cluster headache attacks in subjects with chronic cluster headache.

It is an 18 week, randomized, double-blind, placebo- controlled, bi-center trial.

LXB will be administered as a twice nightly regimen. All subjects will undergo an 8 week Treatment Titration and Optimization Phase.

The main trial endpoint is the change from baseline in average weekly frequency of nocturnal cluster headache attacks over 4-week fixed stable dose of treatment period.

Detailed description: The exact aetiology of cluster headache remains unknown and fundamental questions are still unanswered. However, the tendency of cluster headache attacks to occur during sleep suggests a pivotal role of the hypothalamus, a brain structure that regulates essential body functions such as sleep and the biological clock.

Low sodium oxybate (LXB) is a naturally occurring neurotransmitter and a psychoactive substance that deepens sleep by increasing slow wave sleep and reducing Rapid eye movement (REM) sleep. The chemical name of oxybate is gamma-hydroxybutyrate (GHB). The mechanism of action of LXB is still unknown. It is hypothesized that the therapeutic effects are mediated through GABA-B actions during sleep at noradrenergic and dopaminergic neurons, as well as at thalamocortical neurons.

We hypothesize that cluster headache attacks occur in relation to specific characteristics and time-points of the sleep microstructure and expect that a sleep-deepening treatment with LXB will reduce nocturnal attack-frequency and thereby improve sleep and quality of life.

The main objective of this study is to evaluate the efficacy and safety of LXB in the treatment of nocturnal cluster headache attacks in subjects with chronic cluster headache.

The main trial endpoint is the change from baseline in average weekly frequency of nocturnal cluster headache attacks over 4-week fixed stable dose of treatment period. Nocturnal attacks are defined as occurring after sleep onset during the night until morning awakening between 22:00 and 07:00.

Secondary endpoints include change from baseline in weekly frequency of cluster headache attacks in a 24-hr period (both nocturnal and day-time attacks) over 4-week fixed stable dose of treatment period. Additionally, the i) percentage of participants with a ≥50% reduction from baseline in the weekly number of nocturnal cluster headache attacks, ii) percentage of participants with a ≥50% reduction from baseline in the weekly number of cluster headache attacks in a 24-hr period (both nocturnal and day-time attacks) and iii) cluster headache attack pain intensity will be assessed over the 4-week fixed stable dose of treatment period, iv) Mean change in weekly number of times an abortive medication was taken v) number of patients with improvement in Patient Global Impressions Scale (PGIc) and Clinical Global Impressions Scale (CGIc) vi) improvement of sleep quality, sleep onset, sleep maintenance and sleep efficiency by diary. Optionally, two wearable skin sensors (Actiheart and CALERA Research) will be added for objective sleep and circadian rhythm measurements (including tri-axonal actigraphy, heart rate variability, core body temperature).

Eligibility criteria: Inclusion Criteria:

* Diagnosed with chronic cluster headache according to the International Classification of Headache Disorders (ICHD-III) criteria
* Free of other cluster headache prophylactic medication OR on stable dose for at least 4 weeks
* Not having received a GON (Greater Occipital Nerve) injection or oral prednisone in the previous 3 months
* At least 4 nocturnal cluster headache attacks per week (defined as occurring after sleep onset during the night between 22:00 and 07:00), not clustered at one day but spread across the week.

Exclusion Criteria:

* Suspected of having another trigeminal autonomic cephalalgia (TAC)
* Other headaches if the patient cannot reliably distinguish them from cluster headache attacks
* Significant active or unstable psychiatric disease in the opinion of the investigator
* A history of or current indication of substance abuse
* Unwillingness to refrain from consuming ≤ 1 alcohol unit per day and not later than 8 pm
* Stimulator devices which could influence sleep or cluster headache symptoms, such as an occipital nerve stimulator (ONS), when settings have not been stable for at least three months prior to screening.
* Participation in a clinical trial of an investigation drug or device in the past 30 days
* Women who are pregnant/nursing. Woman of child bearing age need agree to take precautions against becoming pregnant during the trial.
* Contraindications for using low sodium oxybate (LXB):

  * Sleep apnoea syndrome or increased apnoea index (AI \> 15/h)
  * Currently suffering from severe depression and using medication or receiving cognitive therapy. Final choice is at the discretion of the principal investigator.
  * Porphyria
  * Succinic semialdehyde dehydrogenase (SSADH-)deficiency
  * Use of opiates, barbiturates, sedatives (dexmedetomidine, temazepam, oxazepam, midazolam) or LXB (except for the intervention dose) during the study. When benzodiazepine is used before inclusion: a two night washout is needed before the intervention (SP 3) can be started • Prior use of LXB, sodium oxybate (SXB) or Gamma-Hydroxybutyric acid (GHB)

Primary outcomes:
measure: Change in average weekly frequency of nocturnal cluster headache attacks
timeFrame: During 4-week fixed stable dose treatment phase
Secondary outcomes:
measure: Change in percentage of participants with a ≥30% reduction in the weekly number of nocturnal Cluster Headache Attacks
timeFrame: During 4-week fixed stable dose
measure: Change in percentage of participants with a ≥50% reduction in the weekly number of nocturnal Cluster Headache Attacks
timeFrame: During 4-week fixed stable dose
measure: Change in weekly frequency of cluster headache attacks in a 24-hr period during
timeFrame: During a 4-week fixed stable dose
measure: Change in percentage of participants with a ≥30% reduction in the weekly number of cluster headache attacks in a 24-hr period (daytime and nocturnal attacks)
timeFrame: During 4-week fixed stable dose
measure: Change in percentage of participants with a ≥50% reduction in the weekly number of cluster headache attacks in a 24-hr period (daytime and nocturnal attacks)
timeFrame: During 4-week fixed stable dose
measure: Change in pain scale (NRS 0-10)
timeFrame: During 4-week fixed stable dose
Other outcomes:
Locations:
Study officials:
References: